- Home
- MRK vs NVO Comparison
MRK vs NVO Comparison
Compare MRK & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRK | NVO |
|---|---|---|
| Founded | 2000 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.2B | 212.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MRK | NVO |
|---|---|---|
| Price | $105.09 | $51.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 11 |
| Target Price | ★ $111.93 | $54.25 |
| AVG Volume (30 Days) | 16.4M | ★ 17.0M |
| Earning Date | 02-03-2026 | 02-04-2026 |
| Dividend Yield | ★ 3.25% | 2.56% |
| EPS Growth | ★ 58.08 | 10.06 |
| EPS | ★ 7.56 | 3.67 |
| Revenue | ★ $64,235,000,000.00 | $49,580,393,058.00 |
| Revenue This Year | $1.97 | $7.77 |
| Revenue Next Year | $4.96 | $1.86 |
| P/E Ratio | $13.86 | ★ $13.12 |
| Revenue Growth | 1.68 | ★ 16.64 |
| 52 Week Low | $73.31 | $43.08 |
| 52 Week High | $105.84 | $93.80 |
Technical Indicators
Market Signals| Indicator | MRK | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 67.56 | 60.81 |
| Support Level | $96.79 | $47.59 |
| Resistance Level | $100.94 | $48.80 |
| Average True Range (ATR) | 2.50 | 1.13 |
| MACD | 0.03 | 0.34 |
| Stochastic Oscillator | 93.68 | 81.00 |
Price Performance
Historical ComparisonAbout MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.